New study investigates brain fog after CAR-T and bispecific antibody therapies
NCT ID NCT07558057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 225 blood cancer patients receiving CAR-T therapy, bispecific antibodies, or high-dose chemotherapy with stem cell transplant. Researchers will test memory, attention, and thinking skills before treatment and up to 3 years after. The goal is to understand how often cognitive problems occur and how they affect quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could lead to better monitoring and support for cognitive side effects in patients receiving advanced immunotherapies for blood cancers.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new therapy, and results may not apply to all patients or healthcare settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?